Omalizumab

Phase 3Completed
0 watching 0 views this week๐Ÿ“ˆ Rising
77
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Asthma

Conditions

Asthma

Trial Timeline

Oct 1, 2002 โ†’ May 1, 2005

About Omalizumab

Omalizumab is a phase 3 stage product being developed by Daiichi Sankyo for Asthma. The current trial status is completed. This product is registered under clinical trial identifier NCT00232050. Target conditions include Asthma.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (2)

NCT IDPhaseStatus
NCT00219323Phase 3Completed
NCT00232050Phase 3Completed